CFGS
AXSM icon

Concourse Financial Group Securities’s Axsome Therapeutics AXSM Stock Holding History

Concourse Financial Group Securities’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,800
Closed -$86.8K – 2172
2021
Q4 		$106K Buy
2,800
+2,692
+2,493% +$99K 0.01% 972
2021
Q3 		$4K Hold
108
– – ﹤0.01% 2099
2021
Q2 		$7K Hold
108
– – ﹤0.01% 1957
2021
Q1 		$6K Hold
108
– – ﹤0.01% 1909
2020
Q4 		$9K Buy
108
+8
+8% +$598 ﹤0.01% 1710
2020
Q3 		$7K Buy
+100
New +$7.79K ﹤0.01% 1679

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Concourse Financial Group Securities's AXSM Position: Q1 2022 in Review

Concourse Financial Group Securities sold out of Axsome Therapeutics (AXSM) in Q1 2022, closing a stake of 2,800 shares — an estimated $86.8K sold.

Concourse Financial Group Securities first reported a position in AXSM in Q3 2020 and held it in 6 quarters. The position peaked at $106K in Q4 2021. 174 funds tracked by Wall St. Rank hold AXSM as of Q1 2022.

  • Concourse Financial Group Securities reported no remaining Axsome Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Concourse Financial Group Securities sold 2,800 Axsome Therapeutics shares in Q1 2022, an estimated $86.8K.
  • Concourse Financial Group Securities first reported a position in Axsome Therapeutics in Q3 2020 and held it in 6 quarters.
  • Concourse Financial Group Securities's Axsome Therapeutics position peaked at $106K in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2022.

Based on Concourse Financial Group Securities's 13F filing for Q1 2022, filed 9 May 2022.